Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

16 Dec 2020

PURE EXTRACTS TECHNOLOGIES CORP. ANNOUNCES SPECIAL WARRANT OFFERING

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States....

By Microdose

Press Releases

16 Dec 2020

MindMed Upsizes Previously Announced Bought Deal Public Offering

By Microdose

Press Releases

16 Dec 2020

MindMed Announces $50 Million Bought Deal Public Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NEW YORKDec....

By Microdose

Press Releases

16 Dec 2020

Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures

Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s Section 56 exemption....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

15 Dec 2020

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Vancouver, BC – Havn Life Sciences Inc....

By Microdose

Press Releases

15 Dec 2020

Havn Life Sciences announces $5 million Bought Deal Financing

NOT FOR DISTRIBUTION TO U....

By Microdose

Press Releases

15 Dec 2020

Pure Extracts Applauds Health Canada SAP for Psilocybin-Assisted Psychotherapy Inclusion

Special Access Programme Review Considered a Milestone Event Toward Mainstream Acceptance Vancouver, B....

By Microdose

Press Releases

14 Dec 2020

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

Provides Clinical Development Update on 18-MC Based on positive pre-IND meeting with U....

By Microdose

Press Releases

11 Dec 2020

MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)

Post-Financing Cash Reserves of CAD $85m$66....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.